AHA again urged the Food and Drug Administration today to allow health system pharmacies to distribute compounded products to other system facilities located more than one mile away. “The AHA is concerned that the one-mile radius limitation [included in draft guidance last year] is not workable for many hospitals and health systems that have centralized their sterile compounding activities in a single location and distribute compounded products to their other system facilities located more than one mile away,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development, responding to the agency’s request for information on regulatory flexibilities and efficiencies. Instead of the one-mile limit, AHA recommends that the agency allow hospitals and health systems to use the beyond-use date timeframes contained in United States Pharmacopoeia Chapters 797 and 800. AHA also recommended greater FDA oversight of medical device cybersecurity. “We recommend that the FDA proactively set clear measurable expectations for manufacturers before incidents and play a more active role during cybersecurity attacks.”

Related News Articles

Headline
The AHA today proposed additional actions that the Centers for Medicare…
Headline
The Centers for Medicare & Medicaid Services yesterday released a proposed rule that would revise certain requirements for long-term care facilities.
Headline
The AHA said it is generally supportive of the overall concept of the agreement and agency’s goal to create a voluntary network-of-networks that would enable…
Headline
The Centers for Medicare…
Headline
The Department of HHS’ Office of the National Coordinator for Health Information Technology and CMS today extended the deadline to comment on their proposed…
Insights and Analysis
As the 2019 chair of the AHA’s Section for Small or Rural Hospitals, I can attest that AHA is stepping up in a big way to grapple with the issues that affect…